SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units (“RSUs”) to eleven new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in a ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years. He played an instrumental role in Acadia becoming a commercial stage company, providing his significan ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Ran ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Albert Kildani - Senior Vice President, Investor Relations & Corporate Communications Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President: Trofinetide, Rar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Mark Johnson - Vice President of Investor Relations Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Kathie Bishop - Head of Rare Diseases and External Innovation Conference Call Participants ...

Second Quarter 2023 Earnings Call Call Agenda Welcome Jessica Tieszen | Associate Director, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Comm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No.) 12 ...

Financial Data and Key Metrics Changes - In Q1 2023, the company recorded net sales of $118.5 million, representing a 3% increase year-over-year [26] - Gross to net adjustment for the quarter was 29.3%, with year-over-year demand growth up approximately 2% [26] - R&D expenses decreased to $69.1 million from $128.9 million in Q1 2022, primarily due to a $60 million upfront payment recorded in Q1 2022 [26] - SG&A expenses increased slightly to $101.2 million from $96.7 million in Q1 2022, with expectations for flat SG&A expenses for 2023 compared to 2022 [27] Business Line Data and Key Metrics Changes - The NUPLAZID franchise generated steady volumes, with a 2% increase in demand bottles year-over-year [18] - The launch of DAYBUE for Rett syndrome began in mid-April 2023, with positive feedback from healthcare providers and early patient enrollment forms received [13][14] - The company is seeing early indicators of growth in new patient starts for NUPLAZID, despite a contracted market [19] Market Data and Key Metrics Changes - The company is experiencing a return to growth in Parkinson's medication prescriptions and in-person patient visits, which had been negatively impacted during the pandemic [10] - The market share for new-to-therapy patients for NUPLAZID is increasing, driven by real-world evidence publications [9] Company Strategy and Development Direction - The company is focused on four strategic priorities: the launch of DAYBUE, growth of the NUPLAZID franchise, completion of the ADVANCE-2 study for schizophrenia, and development of ACP-204 for Alzheimer's disease psychosis [6][28] - The company is engaging with payers to ensure access to DAYBUE for patients, with discussions ongoing regarding reimbursement policies [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the launch of DAYBUE and the ongoing performance of the NUPLAZID franchise, highlighting the importance of real-world evidence in driving adoption [6][19] - The company anticipates topline results from the ADVANCE-2 study in early 2024, which could lead to a supplemental new drug application [11][24] Other Important Information - The company has completed Phase 1 development of ACP-204 and plans to meet with the FDA to discuss the clinical development plan [7][25] - The company is actively engaging with the Rett community and healthcare providers to support the launch of DAYBUE [21][22] Q&A Session Summary Question: Can you provide more color on payer discussions for DAYBUE? - Management indicated that discussions with payers have been constructive, and they are working to get early patient access through medical exceptions [32] Question: How will the Rett registry help drive adoption for DAYBUE? - Management noted that they are proactively communicating the benefits and tolerability profile of DAYBUE to clinicians and families, which has been well received [36] Question: What key metrics will be provided to gauge the health of the DAYBUE launch? - Management stated that they will provide net revenue and meaningful metrics on the next earnings call, but specific metrics are not available yet [41] Question: What is the current penetration of NUPLAZID in the PDP population? - Management reported that they have increased their share of new patient starts and are over 20% market share across both community and long-term care settings [49] Question: What are the plans for ACP-204's clinical development? - Management indicated that they are eager to move aggressively with the program and will provide more details after meeting with the FDA [58]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No.) 1 ...